End-of-day quote
Shanghai S.E.
06:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
18.7
CNY
|
+0.43%
|
|
+1.74%
|
-4.10%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,959
|
6,339
|
6,268
|
4,845
|
4,646
|
-
|
-
|
Enterprise Value (EV)
1 |
7,959
|
6,339
|
6,268
|
4,845
|
4,646
|
4,646
|
4,646
|
P/E ratio
|
61.5
x
|
33.9
x
|
33
x
|
52.7
x
|
31.7
x
|
21.2
x
|
18
x
|
Yield
|
0.45%
|
0.59%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
20.4
x
|
10.7
x
|
9.66
x
|
10.5
x
|
7.62
x
|
5.3
x
|
4.51
x
|
EV / Revenue
|
20.4
x
|
10.7
x
|
9.66
x
|
10.5
x
|
7.62
x
|
5.3
x
|
4.51
x
|
EV / EBITDA
|
53.1
x
|
27.6
x
|
24.1
x
|
28.4
x
|
20.1
x
|
14
x
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
5.19
x
|
3.76
x
|
3.41
x
|
2.54
x
|
2.26
x
|
2.06
x
|
1.89
x
|
Nbr of stocks (in thousands)
|
248,454
|
248,454
|
248,454
|
248,454
|
248,454
|
-
|
-
|
Reference price
2 |
32.03
|
25.51
|
25.23
|
19.50
|
18.70
|
18.70
|
18.70
|
Announcement Date
|
2/2/21
|
2/21/22
|
2/21/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
390.4
|
593.4
|
649.2
|
460.7
|
610
|
876.5
|
1,030
|
EBITDA
1 |
149.8
|
229.9
|
259.7
|
170.6
|
231
|
330.7
|
-
|
EBIT
1 |
130.4
|
204
|
229.1
|
117.3
|
176.5
|
263
|
333
|
Operating Margin
|
33.39%
|
34.38%
|
35.29%
|
25.47%
|
28.93%
|
30.01%
|
32.33%
|
Earnings before Tax (EBT)
1 |
136.9
|
217.3
|
239.5
|
63.8
|
198
|
283
|
348
|
Net income
1 |
118.6
|
186.4
|
190.8
|
129.9
|
146
|
220.2
|
259
|
Net margin
|
30.37%
|
31.41%
|
29.39%
|
28.2%
|
23.93%
|
25.12%
|
25.15%
|
EPS
2 |
0.5207
|
0.7521
|
0.7636
|
0.3700
|
0.5900
|
0.8833
|
1.040
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
0.1438
|
0.1504
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/2/21
|
2/21/22
|
2/21/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
10.3%
|
11.6%
|
10.8%
|
4.87%
|
6.85%
|
9.5%
|
10.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
6.170
|
6.790
|
7.400
|
7.690
|
8.260
|
9.080
|
9.870
|
Cash Flow per Share
2 |
0.3100
|
0.5800
|
0.6300
|
1.080
|
0.4900
|
0.8200
|
1.340
|
Capex
1 |
30.5
|
91.3
|
138
|
25.8
|
510
|
478
|
-
|
Capex / Sales
|
7.8%
|
15.39%
|
21.29%
|
5.6%
|
83.61%
|
54.54%
|
-
|
Announcement Date
|
2/2/21
|
2/21/22
|
2/21/23
|
2/23/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -4.10% | 641M | | -24.88% | 7.32B | | +7.04% | 6.66B | | +15.10% | 5.5B | | -15.87% | 4.88B | | +14.96% | 4.1B | | -21.75% | 3.89B | | -25.03% | 2.83B | | +44.01% | 2.31B | | +1.98% | 2.07B |
Medical Equipment
|